Business Context and Reporting Period
This Form 8-K was filed by Pieris Pharmaceuticals, Inc. on May 22, 2019. The registrant is an emerging growth company incorporated in Nevada with principal executive offices in Boston, MA. The filing serves as a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure regarding clinical data and does not contain financial statements or quantitative financial metrics.
Material Changes
The material event reported is the presentation of clinical data related to the company's phase 1a study of PRS-060. This data was presented at the American Thoracic Society 2019 International Conference on May 22, 2019. The associated conference poster is included as Exhibit 99.1.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on financial outlook, or specific risk factors beyond the standard regulatory language. The disclosure explicitly states that the information under Item 7.01, including Exhibit 99.1, shall not be deemed "filed" for any purpose and shall not be incorporated by reference into any other filing under the Securities Act or Exchange Act, except as expressly set forth by specific reference.
Investor Verification Checklist
- Verify the clinical data details in the attached Exhibit 99.1 (Conference Poster) regarding the PRS-060 phase 1a study.
- Confirm the status of the PRS-060 development program in subsequent filings, as this 8-K does not provide future trial timelines.
- Note that the clinical data presented is not deemed "filed" for legal purposes under the Securities Act or Exchange Act.
- Review the company's most recent 10-K or 10-Q for actual financial metrics, as this 8-K contains no financial data.